Patients who eliminate peanut. Patients with positive open label oral food challenge (exclude oral around symptom) less than or equal to 1.4 g of peanuts, which contained 35.7 mg peanut protein (only VLOIT group).
Patients with uncontrollable asthma or atopic dermatitis. Patients with chronic urticaria. Patients who do immunotherapy of other foods within 2 hours before and after this treatment. Patients whom the doctor assesses ineligible.
Very low-dose oral immunotherapy with peanut. Participants take 0.0092 mg of peanut protein daily as first dose. The doses are increased double times every 7 intakes up to 5.74 mg of peanut protein.
介入コード / Code
介入キーワード /Keyword
主たる評価項目 / Primary Outcome(s)
試験開始時と試験開始12か月後のピーナッツOFCの陰性摂取量の前後差。
Difference of successfull comsumed dose of peanut oral food challenge between baseline and month 12.
副次的な評価項目 / Secondary Outcome(s)
試験開始時と試験開始12か月後のピーナッツ特異的IgEおよびIgG4、Ara h 2特異的IgEおよびIgG4、落花生液の皮膚プリックテスト(Skin Prick Test ; SPT)の前後差。試験開始12か月後のピーナッツ特異的IgEについてVLOIT群とピーナッツ特異的IgEをマッチさせた除去群の群間差。試験開始時と開始12か月後の落花生液のSPTの変化量についてのVLOIT群と除去群の群間差。試験開始時と試験開始12か月後のピーナッツ特異的IgG4・Ara h 2特異的IgEおよびIgG4変化率についてのVLOIT群と除去群間の群間差
Difference of peanut specific-IgE and IgG4, Ara h 2 specific-IgE and IgG4, and wheal size of peanut SPTs between baseline and month 12. Difference of peanut specific-IgE at month 12 between the VLOIT group and the Control group, which consisted of peanut specific-IgE at baseline matched 20 patients who avoid peanut for 12 months. Difference of absolute change in wheal size of peanut SPTs from baseline to month 12 between the VLOIT group and the Control group. Difference of parcentage change in peanut specific-IgG4 and Ara h 2 specific-IgE and IgG4 from baseline to month 12 between the VLOIT group and the Control group.